Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Profound MedicalPROF +0.34%73 EV-to-Revenue is 9.81 as of Sep. 12, 2026, which is 56% below its 10-year median of 22.10. GuruFocus rates PROF with a GF Score™ of 73/100 and a GF Value™ of $10.61 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 813 Medical Devices & Instruments companies, Profound Medical ranks worse than 83.76% on this metric.
EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Profound Medical's enterprise value is $187.30 Mil.
Profound Medical's Revenue for the trailing twelve months (TTM) ended in Jun. 2026 was $19.09 Mil. Therefore, Profound Medical's EV-to-Revenue for today is 9.81.
The historical rank and industry rank for Profound Medical's EV-to-Revenue or its related term are showing as below:
PROF'
s EV-to-Revenue Range Over the Past 10 Years
Min: 4.51 Med: 22.1 Max: 77.19
Current: 9.81
During the past 12 years, the highest EV-to-Revenue of Profound Medical was 77.19. The lowest was 4.51. And the median was 22.10.
PROF's EV-to-Revenue is ranked worse than 83.76% of 813
companies
in the Medical Devices & Instruments industry
Industry Median: 2.85
vs PROF: 9.81
As of today (2026-09-12), Profound Medical's stock price is $5.98.
Profound Medical's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was $0.59. Therefore, Profound Medical's PS Ratio for today is 10.20.
Profound Medical's share price for today is $5.98.
Profound Medical's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.59.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Profound Medical EV-to-Revenue Related Terms
Profound Medical EV-to-Revenue Historical Data
* Premium members only.
The historical data trend for Profound Medical's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Profound Medical's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Profound Medical EV-to-Revenue vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Profound Medical's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Profound Medical's EV-to-Revenue falls into.
Profound Medical's current Enterprise Value is $187.30 Mil.
Profound Medical's Revenue for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $19.09 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Profound Medical (PROF) has a EV-to-Revenue of 9.81 as of Sep. 12, 2026. EV to Revenue ratio is the company's enterprise value divided by sales. View historical data on Profound Medical and its competitors. This is 56% below median its historical median of 22.10. Over the past decade, Profound Medical's EV-to-Revenue has ranged from 4.51 to 77.19. According to the industry distribution chart, Profound Medical ranks #681 out of 813 companies in the Medical Devices & Instruments industry, placing it in the top 83.8%.
Is Profound Medical's EV-to-Revenue too high?
Profound Medical's current EV-to-Revenue of 9.81 is 56% below median its 10-year median of 22.10. Over the past 10 years, this metric has ranged from a low of 4.51 to a high of 77.19. The Medical Devices & Instruments industry median EV-to-Revenue is 2.85. Profound Medical's value of 9.81 is 244.2% above this industry median. Based on the distribution chart, Profound Medical ranks #681 out of 813 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Profound Medical has a GF Score™ of 73/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Profound Medical's EV-to-Revenue compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Profound Medical ranks #681 out of 813 companies for EV-to-Revenue. This places Profound Medical in the lower half of its industry. The industry median EV-to-Revenue is 2.85. Profound Medical's value of 9.81 is 244.2% above this benchmark. Historically, Profound Medical's own EV-to-Revenue has ranged from 4.51 to 77.19 over the past decade. While the company's 10-year median is 22.10 vs. the industry median of 2.85, Profound Medical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-Revenue for a Medical Devices & Instruments company?
The median EV-to-Revenue among Medical Devices & Instruments companies is 2.85, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-Revenue significantly above this median, while those in the bottom quartile fall well below. However, EV-to-Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Profound Medical's current EV-to-Revenue of 9.81 is 244.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-Revenue mean?
A high EV-to-Revenue can signal that a stock is expensive relative to its fundamentals. EV to Revenue ratio is the company's enterprise value divided by sales. View historical data on Profound Medical and its competitors. For the Medical Devices & Instruments industry, the median EV-to-Revenue is 2.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Profound Medical's current EV-to-Revenue is 9.81, which is 56% below median its own 10-year median of 22.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Profound Medical stock overvalued right now?
Based on GuruFocus' analysis, Profound Medical (PROF) is currently considered Possible Value Trap. The stock's GF Value™ is $10.61, compared to a current price of $5.98 — trading 43.6% below its estimated fair value. The current EV-to-Revenue is 9.81, which is 56% below median its 10-year median of 22.10 and 244.2% above the Medical Devices & Instruments industry median of 2.85. Profound Medical's overall GF Score™ is 73/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-Revenue calculated?
EV-to-Revenue is calculated from a company's financial statements. For Profound Medical (PROF), the current EV-to-Revenue is 9.81 as of Sep. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Profound Medical (PROF) Overvalued in 2026?
Based on GuruFocus' analysis, Profound Medical stock appears to be undervalued.
The current stock price of $5.98 is trading 43.6% below its estimated GF Value™ of $10.61.
GuruFocus considers Profound Medical to be Possible Value Trap.
Key valuation signals for PROF:
EV-to-Revenue: 9.81 (56% below median its 10-year median of 22.10)
GF Value™: $10.61 vs. price of $5.98 (43.6% below fair value)
Industry Position: 244.2% above the Medical Devices & Instruments median (#681 of 813)
No single metric tells the full story. See the PROF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.
73GF Score
Get the complete analysis for PROF
EV-to-Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PROF has been successfully added to your 
